1-3 of 3
Jennifer Osborn, MD
Close
Sort by
Journal Articles

A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Interim Study Results,

Lijun Dai, MD, PhD, Amy O'Sullivan, RN, BSN, Ryan Kennedy, BS, Mohammad Abbas, MD, Yongli Shuai, MS, Vida Almario Passero, MD, Carrie Andreas, PA-C, Diane Gardner, MSN, CRNP, BC, Robert L Redner, MD, G. David Roodman, MD, PhD, Stanley M. Marks, MD, Anastasios Raptis, MD, Jing-Zhou Hou, MD, PhD, Daniel Petro, MD, Min Sun, MD, PhD, Terry Evans, MD, Louis V. Pietragallo, MD, John K. Waas, DO, J. Franklin Viverette, MD, Jennifer Osborn, MD, Vincent Reyes, MD, Richard Pinkerton, DO, Theodore Crandall, MD, Ronald Fierro, MD, Robert Volkin, MD, Daniel Normolle, PhD, Markus Y. Mapara, MD, PhD, Suzanne Lentzsch, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 4142.
https://doi.org/10.1182/blood.V118.21.4142.4142
Published: 2011
Journal Articles

Phase II Study of Short Course CHOP-Rituximab Followed by 90-Y Ibritumomab Tiuxetan as First-Line Treatment for Follicular Lymphoma: An Update and Extension of Preliminary Findings on Predictors of Relapse.

Rachel C. Jankowitz, MD, Kenneth A. Foon, MD, The Minh Luong, M.Sc, Stephanie R. Land, PhD, Nicholas A. DeMonaco, MD, Steven H. Swerdlow, MD, Judith Joyce, MD, Jennifer Osborn, MD, Terry Evans, MD, Samuel A. Jacobs, MD
Journal: Blood
Blood (2008) 112 (11): 2001.
https://doi.org/10.1182/blood.V112.11.2001.2001
Published: 2008
Journal Articles

Phase II Trial of Abbreviated CHOP-Rituximab Followed by 90 Y Ibritumomab Tiuxetan (Zevalin) and Rituximab in Patients with Previously-Untreated Follicular Non-Hodgkin Lymphoma (NHL).

Nicholas A. DeMonaco, MD, Michael Wu, MD, Jennifer Osborn, MD, Terry Evans, MD, Kenneth A. Foon, MD, Steven H. Swerdlow, MD, Jeffrey Kant, MD, PhD, Judith Joyce, MD, Stephanie R. Land, PhD, Samuel A. Jacobs, MD
Journal: Blood
Blood (2005) 106 (11): 2449.
https://doi.org/10.1182/blood.V106.11.2449.2449
Published: 2005